(Q35207879)

7 August 2017

1 reference

title

Preventive and therapeutic approaches to viral agents of bioterrorism (English)

1 reference

7 August 2017

0 references

Michael S Bronze

1

1 reference

7 August 2017

Ronald A Greenfield

series ordinal

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

8

1 reference

7 August 2017

issue

16

1 reference

7 August 2017

page(s)

740-745

1 reference

Smallpox: a potential agent of bioterrorism

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Smallpox as a Biological Weapon

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Modeling potential responses to smallpox as a bioterrorist weapon

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Field trials of methisazone as a prophylactic agent against smallpox

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Cidofovir in the therapy and short-term prophylaxis of poxvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Complications of smallpox vaccination. I. National survey in the United States, 1963.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Emergency response to a smallpox attack: the case for mass vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

A model for a smallpox-vaccination policy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Containing bioterrorist smallpox.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Preventing the return of smallpox

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Can postexposure vaccination against smallpox succeed?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

The persistence of neutralizing antibodies after revaccination against smallpox

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Smallpox in Europe, 1950-1971

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

1 reference

7 January 2021

How contagious is vaccinia?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

The new cell culture smallpox vaccine should be offered to the general population

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

A review of compounds exhibiting anti-orthopoxvirus activity in animal models

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

In vitro activity of potential anti-poxvirus agents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Effect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Hemorrhagic fever viruses as biological weapons: medical and public health management

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Arenaviruses other than Lassa virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Epitopes involved in antibody-mediated protection from Ebola virus

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Effective vaccine for lassa fever

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Inhibition of arenavirus multiplication in vitro by phenotiazines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Mode of inactivation of arenaviruses by disulfide-based compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Defense against filoviruses used as biological weapons

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Treatment of Bolivian hemorrhagic fever with intravenous ribavirin.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Effect of ribavirin and immune serum on Junin virus-infected primates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

The potential use of influenza virus as an agent for bioterrorism

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

Nipah virus--a potential agent of bioterrorism?

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902778-8

7 January 2021

10.1016/S1359-6446(03)02778-8

Identifiers

DOI

1 reference

7 August 2017

1 reference